WO2005090576A1 - 百日咳感染症予防用dna構築物 - Google Patents
百日咳感染症予防用dna構築物 Download PDFInfo
- Publication number
- WO2005090576A1 WO2005090576A1 PCT/JP2005/004430 JP2005004430W WO2005090576A1 WO 2005090576 A1 WO2005090576 A1 WO 2005090576A1 JP 2005004430 W JP2005004430 W JP 2005004430W WO 2005090576 A1 WO2005090576 A1 WO 2005090576A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mutation
- amino acid
- acid sequence
- dna
- dna construct
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to a polynucleotide for use in the prevention of pertussis infection and a polynucleotide expressing the polynucleotide.
- Pertussis is an acute respiratory tract infection in children caused by infection with Bordetella pertussis. Vaccination is the most effective way to control this infection.
- the pertussis vaccine currently inoculated in Japan is a cell-free vaccine that uses pertussis toxin and fibrillar hemagglutinin as major protective antigens.
- the protective antigen used in this cell-free vaccine was fractionated from the culture supernatant of B. pertussis and then detoxified with formalin. The production of this cell-free vaccine requires a large-scale cultivation of B. pertussis. From the viewpoint of cost and biosafety, there is a need for the development of a new vaccine that is cheaper and safer to produce.
- toxin antigens expressed as recombinant proteins can be mentioned as candidate substances for a new whooping cough vaccine, but it is difficult to induce a prophylactically effective toxin neutralizing antibody with these recombinant antigens. is there.
- the DNA vaccine technology is a technology for inducing an immune response by directly expressing a vaccine antigen gene in a living body, and is expected to be able to produce a vaccine at a lower cost than a conventional vaccine. ing.
- the effectiveness of DNA vaccines using the protective antigen genes for many infectious diseases has been studied.
- the present inventors have now found that, in a peptide fragment consisting of amino acid 111-180 in the pertussis toxin S1 subunit, the ninth arginine residue is changed to a lysine residue and Z or By expressing a peptide fragment having a mutation of the 129th glutamic acid residue to a glycine residue, it is possible to suppress the toxic activity and induce a significant immunoprotective effect against B. pertussis. Was obtained.
- the present invention is based on these findings.
- an object of the present invention is to provide a polypeptide used for the prevention or treatment of pertussis infection, a DNA construct capable of expressing the polypeptide, and a pharmaceutical composition comprising the same.
- polypeptide according to the present invention has an amino acid sequence of pertussis toxin S1 submit, which has 180 amino acids,
- It has an amino acid sequence having at least one mutation selected.
- the DNA construct according to the present invention comprises the DNA encoding the polypeptide in a form capable of expressing the same.
- composition according to the present invention comprises the polypeptide or the DNA construct.
- a polypeptide having no toxicity or a combination of the polypeptide gene is used. Since these DNA constructs are used as immunogens, there is no need to mass-cultivate B. pertussis at biosafety level 2 in their production.For example, biosafety level 1 Escherichia coli can be handled. Thus, a composition for preventing pertussis can be produced. Furthermore, according to the present invention, even if a polypeptide or DNA construct is directly inoculated into a living body, it is possible to prevent pertussis infection, which is highly safe for the host without causing toxin activity in the host cell.
- FIG. 1 is a view showing the construction of a plasmid (pcDNA / C180-9K / 129G) into which a C180-9K / 129G gene has been inserted.
- FIG. 1 shows the C200 gene lacking the N-terminal or C-terminal of the pertussis toxin S1 subunit.
- FIG. 1 is a schematic diagram of the C180 gene, C160 gene, and N40 gene.
- FIG. 3 shows the results of Northern plot analysis in COS-7 cells into which the S1, C200, C180, C160, or N40 gene was introduced.
- FIG. 4 shows the results of Western blot analysis in COS-7 cells into which the S1, C200, C180, C160, or N40 gene was introduced.
- FIG. 5 shows the concentration of anti-pertussis toxin antibody in the serum of mice inoculated with truncated S1 gene (C200 gene, C180 gene, C160 gene, or N40 gene).
- FIG. 6 shows the peripheral blood leukocyte count when pertussis toxin was administered to mice inoculated with truncated S1 gene.
- FIG.7 shows a schematic diagram of the mutant C180 gene (C180-9K gene, C180-129G gene, C180-9K / 129G gene) and Western blot analysis of COS-7 cells transfected with the mutant C180 gene. The result is shown.
- FIG. 8 shows the concentration of anti-pertussis toxin antibody in the serum of mice inoculated with the mutant C180 gene (C180-9K gene, J180-129 ⁇ gene, or C180-9KZ129G gene).
- FIG. 9 shows the peripheral blood leukocyte count when pertussis toxin was administered to mice inoculated with the mutant C180 gene (C180-9K gene, J180-129 ⁇ gene, or C180-9KZ129G gene).
- FIG. 10 is a photograph of a stable expression strain obtained by transfecting pcDNA, pcDNA / C180-9K, pcDNA / C180-129G, or pcDNA / C180-9K / 129G into CHO cells.
- the amino acid sequence encoding the polypeptide according to the present invention comprises the first 180 amino acids (hereinafter referred to as “C180”) in the pertussis toxin S1 subunit, and further comprises (a) Mutation of the 9th arginine residue to a lysine residue (hereinafter referred to as “R9K mutation” and V), and (b) mutation of the 129th glutamic acid residue to a glycine residue (hereinafter “E129G mutation”) ) Having at least one mutation selected from the group consisting of:
- the polypeptide according to the present invention has an R9K mutation (hereinafter, referred to as “C180-9K”).
- the polypeptide according to the present invention has an E129G mutation (hereinafter, referred to as “C180-129G”). Furthermore, according to another preferred embodiment of the present invention, it has an R9K mutation and an E129G mutation (hereinafter, “C180-9KZ129G” t ⁇ ).
- Examples of the amino acid sequence of C180 having no mutation include those having amino acids 2-181 in the amino acid sequence represented by SEQ ID NO: 2.
- the first methionine residue in SEQ ID NO: 2 is one that is eliminated after translation.
- the amino acid sequence of C180 having no mutation is the amino acid sequence represented by No. 2-181 in SEQ ID NO: 2 at a site other than R9K mutation and Z or E129G mutation. , Where one or several amino acids have been substituted, deleted or added.
- the polypeptide according to the present invention, represented by the amino acid sequence of C180 without this mutation also has an immunity-inducing activity that can be used for prevention or treatment of pertussis infection.
- the range of "one or several" means preferably about 113, more preferably about 112.
- the amino acid sequence of C180 having no mutation is a partial sequence of the amino acid sequence represented by No. 2-181 of SEQ ID NO: 2, and It comprises a partial sequence containing the mutation and the site of the Z or E129G mutation.
- the polypeptide according to the present invention, represented by such a subsequence, is also suitable for pertussis infection It has an immunity-inducing activity that can be used for prevention or treatment of the disease.
- the partial sequence preferably includes a partial sequence represented by No. 3-180 in SEQ ID NO: 2.
- residues 34-36 encode a lysine residue. It has a nucleotide sequence replaced by codons. Such substitution preferably includes substitution of residues 34-36 with an adenine residue (A), an adenine residue (A), and a guanine residue (G).
- the DNA according to the present invention is a nucleotide sequence represented by the nucleotide sequence represented by No. 10-549 in SEQ ID NO: 1, in which the 394-396 residue is a glycine residue.
- the DNA according to the present invention comprises the nucleotide sequence of Nos. 10 to 549 in SEQ ID NO: 1 in which residues 34 to 36 are lysine residues. And a nucleotide sequence in which residues 394-396 have been substituted with a codon encoding a glycine residue.
- substitutions preferably include substitution of residues 34-36 with AAG and substitution of residues 395-396 with GC.
- the DNA construct according to the present invention comprises a DNA encoding the polypeptide according to the present invention in a form capable of expressing the polypeptide, whereby the polypeptide according to the present invention can be expressed.
- “comprising an expressible form” refers to a mode that allows expression of a transgene (DNA) under the control of appropriate regulatory elements (eg, promoters, enhancers, transcription terminators, etc.). Means that the transgene has been inserted into the DNA construct.
- the DNA encoding C180 can be cloned by preparing a PCR primer based on the sequence information of a known Bordetella pertussis gene, and performing a PCR reaction on Bordetella pertussis genomic DNA. These crawling, for example, It can be easily performed by those skilled in the art according to literature such as Molecular Cloning 2nd Edt., Cold Spring Harbor Laboratory Press (1989).
- the DNA encoding C180-9K, C180-129G, or C180-9K / 129G is a DNA encoding C180, for example, a mutagenesis method using PCR, site-directed mutagenesis. It can be easily obtained by applying an induction method or the like, and specifically, it can be easily performed with reference to the above-mentioned literature such as Molecular Cloning.
- the DNA construct according to the present invention can be used in a form inserted into a non-viral vector or a viral vector so that it can be expressed.
- a vector comprising a DNA construct according to the present invention.
- Methods for preparing and administering these non-viral vectors and viral vectors are already known to those skilled in the art. For example, separate experimental medicine, basic technology of gene therapy, Yodosha, 1996; separate experimental medicine, gene Introductory & Expression Analysis Experimental Method, Yodosha, 1997; Gene Therapy Development Research Handbook, edited by The Japanese Society for Gene Therapy, NTS, 1999.
- the non-viral vector is not particularly limited as long as it is a vector capable of expressing a target gene in a mammalian organism, and is preferably a plasmid.
- the non-viral vector include pcDNA3.1, pZeoSV ⁇ pBK-CMV (Invitrogen, Stratagene) and pCAGGS (Gene 108, 193-200 (1991)), and preferably pcDNA3.1.
- the vector according to the present invention can be prepared by inserting the above gene so that it can be expressed in the downstream region of the promoter of one of these expression vectors.
- virus vector examples include adenovirus, adeno-associated virus, herpes virus, vaccinia virus, box virus, polio virus, symbisinores, Sendai virus, SV40, Powers that can include immunodeficiency virus (HIV) and the like are not limited thereto.
- adenovirus adeno-associated virus
- herpes virus vaccinia virus
- box virus polio virus
- symbisinores Sendai virus
- SV40 Powers that can include immunodeficiency virus (HIV) and the like are not limited thereto.
- HIV immunodeficiency virus
- the polypeptide according to the present invention is obtained, for example, by introducing the above-described vector into a suitable host, culturing the host, and producing and accumulating the polypeptide according to the present invention in a culture.
- the polypeptide according to the present invention can be more isolated and purified.
- the host include Escherichia coli, insect cells and mammalian cells, and are preferably mammalian cells.
- the method of introducing the vector into the host, the culture conditions of the host, etc. Is appropriately selected by those skilled in the art. For isolation and purification of the polypeptide according to the present invention, known methods can be used.
- C180 contains not only a site for inducing immunity to pertussis toxin but also a toxic active site, but the polypeptide according to the present invention mainly efficiently induces antibody production and hardly expresses toxic activity. Therefore, the polypeptide according to the present invention can be suitably used for prevention of pertussis infection in mammals.
- a method for preventing pertussis infection comprising administering to a subject a prophylactically effective amount of a polypeptide according to the present invention. Further, the polypeptide according to the present invention can be used for treatment of pertussis infection.
- a method for treating pertussis infection comprising administering to a subject a therapeutically effective amount of a polypeptide according to the present invention.
- treatment refers to amelioration of an established condition
- prevention refers to preventing the establishment of a condition in the future.
- the subject is usually a human, preferably an infant.
- a known method for inducing immunity can be used.
- a known adjuvant may be used together with a known adjuvant to prepare a solution or suspension. It can be administered by subcutaneous injection, intramuscular injection or oral administration.
- the amount of the polypeptide according to the present invention to be administered may be a prophylactically or therapeutically effective amount, and the specific amount is determined by those skilled in the art.
- the dose is preferably adjusted depending on the age, body weight, etc. of the subject, and such adjustment of the dose is appropriately performed by a physician.
- the dose is usually 110 gZ kg body weight, preferably 2-5 ⁇ g Z body weight kg.
- the polypeptides according to the present invention are pharmaceutically safe within the above dosage ranges.
- the DNA construct according to the present invention which can express the polypeptide according to the present invention, can also be suitably used as a DNA vaccine for preventing pertussis infection in mammals.
- a method for preventing pertussis infection comprising administering to a subject a prophylactically effective amount of a DNA construct or vector according to the present invention.
- the DNA construct according to the invention can also be used for the treatment of pertussis infection. It is possible.
- a method of treating pertussis infection comprising administering to a subject a therapeutically effective amount of a DNA construct or vector according to the present invention.
- Examples of a method for introducing the DNA construct according to the present invention into a subject include, for example, an in vivo method in which the DNA construct is directly introduced into the body, and a method in which certain cells are removed from the subject and the DNA construct is introduced into the cells outside the body. There is an ex vivo method for returning the cells to the body (Gene Handbook for Research and Development of Gene Therapy, edited by The Japan Society for Gene Therapy, NTS, 1999).
- an in vivo method for example, a DNA construct according to the present invention is dissolved in an appropriate solvent (a buffer solution such as PBS, physiological saline, sterilized water, etc.), and if necessary, sterilized by filtration with a filter or the like, followed by filtration.
- an appropriate solvent a buffer solution such as PBS, physiological saline, sterilized water, etc.
- An injection can be prepared by filling in a sterile container, and can be administered by injection to a subject.
- the injection can be injected subcutaneously, intradermally, intravenously, or directly into the cerebrospinal fluid into the muscle or other tissue of the subject.
- a conventional carrier or the like may be added to the injection, if necessary.
- the DNA construct according to the present invention can be administered orally and nasally to respiratory mucosal cells.
- the DNA construct according to the present invention is encapsulated in a ribosome made of a lipid bilayer, and the ribosome is fused with an inactivated Sendai virus (Hemagglutinating virus of Japan: HVJ) to form HVJ-ribosome.
- Sendai virus Hemagglutinating virus of Japan: HVJ
- the DNA construct according to the present invention may be coated on gold microparticles and transdermally delivered by a particle impactor or "gene gun" (Tang, 1992, Nature 356: 152-154).
- the ex vivo method include a method of directly injecting the DNA construct according to the present invention into cells using an electoral poration method, a lipofection method, a calcium phosphate coprecipitation method, a DEAE-dextran method, a micro glass tube, or the like. No.
- the amount of the DNA construct according to the present invention to be administered may be a prophylactically or therapeutically effective amount, and the specific amount is determined by those skilled in the field of gene therapy.
- the dose is preferably adjusted according to the age, weight, etc. of the subject, and such adjustment of the dose is appropriately performed by a physician.
- the dose is usually 2 to 40 gZ kg body weight, preferably 4 to 36 / z gZ body weight kg.
- the DNA construct according to the present invention has the above-mentioned investment. It is pharmaceutically safe within the dosage range.
- the polypeptide or DNA construct or vector according to the present invention can be administered to a subject as a pharmaceutical composition.
- a pharmaceutical composition comprising a polypeptide according to the present invention.
- a pharmaceutical composition comprising a DNA construct according to the present invention or a vector according to the present invention.
- the above-mentioned pharmaceutical composition can be used for prevention and further treatment of pertussis infection.
- a polypeptide according to the present invention in the manufacture of a prophylactic or therapeutic agent for pertussis infection.
- the DNA construct or vector according to the present invention in the manufacture of a prophylactic or therapeutic agent for pertussis infection.
- the pharmaceutical composition according to the present invention can further include a pharmaceutically acceptable carrier.
- pharmaceutically acceptable carriers such as vehicles, excipients, diluents, adjuvants and the like are appropriately selected by those skilled in the art according to the administration route and the like.
- the DNA of the pertussis toxin S1 subunit was amplified by PCR using genomic DNA derived from Bordetella pertussis Tohama as type III using the following primers.
- the following primers include restriction sites for Hindlll and BamHI (underlined), respectively.
- mSl— R Reverse: 5 CGGGATCCTTACTAGAACGAATACGCGAT-3 '(SEQ ID NO:
- the amplification by PCR was performed using Takara PCR thermal cycler MP (registered trademark: manufactured by Takara Shuzo Co., Ltd.).
- the temperature conditions of the cycle reaction were one cycle of 94 ° C. for 20 seconds, 68 ° C. for 3 minutes, and 72 ° C. for 10 minutes, which was 30 cycles.
- the PCR product was treated with Hindlll and BamHI, and incorporated into a eukaryotic cell expression vector (pcDNA. 3.1 (+); manufactured by Invitrogen).
- the thus obtained pcDNAZSl plasmid was purified from E. coli JM109 strain using end-free plasmid preparation kits (manufactured by Qiagen).
- the C180 gene encoding the N-terminal 180 amino acid residues of the pertussis toxin S1 subunit and its plasmid vector (pcDNAZC180) were produced in the same manner as in Reference Example 1 using the following primers.
- C180—R reverse: 5 CGGGATCCTTACTACGATGTGTAGGGGTTGGG-3 ′ (SEQ ID NO: 5).
- the C200 gene encoding the N-terminal 200 amino acid residues of the pertussis toxin S1 subunit and its plasmid vector (pcDNAZC200) were produced in the same manner as in Reference Example 1 using the following primers.
- C200—R Reverse: 5 CGGGATCCTTACTAAGCGCCTATCACCGGCGC-3 ′ (SEQ ID NO: 6).
- the C160 gene encoding the N-terminal 160 amino acid residues of the pertussis toxin S1 subunit and its plasmid vector (pcDNAZC160) were produced in the same manner as in Reference Example 1 using the following primers.
- C160—R reverse: 5 CGGGATCCTTACTACTCCGTGGTCGTGGTCTC-3 ′ (SEQ ID NO: 7).
- N40 gene lacking the N-terminal 40 amino acid residues of the pertussis toxin S1 subunit and a plasmid vector (pcDNAZN40) incorporating the N40 gene were produced in the same manner as in Reference Example 1 using the following primers.
- N40-F Forward: 5'- CCCAAGCTT
- mSl— R Reverse: 5 CGGGATCCTTACTAGAACGAATACGCGAT-3 '(SEQ ID NO:
- the C180 gene having the R9K mutation and the E129G mutation was produced by PCR using a combination of the following primers (mSl-9KZF, E129G / R, E129GZF and C180R) with the S1 gene as type III.
- two types of PCR products were obtained by a PCR method using a combination of primers of mSl-9KZF and E129GZR, or E129GZF and C180R.
- these two kinds of PCR products were purified according to a conventional method, and treated by a PCR method using mSl-9K / F and C180R primers to obtain a C180 gene having an R9K mutation and an E129G mutation.
- the inserted plasmid vector (pcDNA / C180-9K / 129G) was produced in the same manner as in Reference Example 1.
- the following primers contain Hindlll and BamHI restriction enzyme sites (underlined) and R9K and E129G gene mutations (in parentheses), respectively.
- E129G / F 5'-CTGGCCACCTACCAGAGC [GGC]
- E129G / R 5'-GCGCCGGTGTGCCAGATA [GCC]
- FIG. 1 shows the constructed pcDNA / C180-9K / 129G.
- the C180 gene having the R9K mutation was produced in the same manner as in Reference Example 1 using the S1 gene as type III and the following primers.
- a plasmid vector (pcDNAZC180-9KZ129G) into which the C180 gene having the R9K mutation was inserted was produced in the same manner as in Reference Example 1.
- the primers below contain the Hindlll and BamHI restriction enzyme sites (underlined) and the R9K mutation (in parentheses), respectively.
- C180R reverse: 5, -CGO ⁇ TTACTACGATGTGTAGGGGTTGGG-3, (sequence number 5).
- Plasmid vector (ecDNA / C180—129G g3 ⁇ 4
- the C180 gene having the E129G mutation with the S1 gene as (mSl-F, E129G / R, E129G / F, and CI 80R).
- two types of PCR products were obtained by a PCR method using a combination of mSl-F and E129G / R, or a combination of E129G / F and C180R primers.
- these two PCR products were purified according to a standard method.
- the C180 gene having the E129G mutation was obtained by a PCR method using the primer 1801 ⁇ primer.
- a plasmid vector (pcDNA / C180-129G) incorporating the gene thus obtained was produced in the same manner as in Reference Example 1.
- the following primers contain Hindlll and BamHI restriction enzyme sites (underlined) and E129G gene mutation (in parentheses), respectively.
- mSl-F 5,-CCCAAGCTTGCCACCATGGACGATCCTCCCGCCACC-3, (SEQ ID NO: 3);
- E129G / F 5'-CTGGCCACCTACCAGAGC [GGC]
- E129G / R 5'-GCGCCGGTGTGCCAGATA [GCC]
- the following expression analysis was performed using pcDNA, pcDNA / S1, pcDNA / C200, pcDNA / C180, pcDNA / C160, and pcDNAZN40.
- the peptide fragment expressed by the plasmid is as shown in the schematic diagram of FIG.
- ECL For detection of pertussis toxin SI mRNA, ECL direct Using a pertussis toxin S1 gene that was labeled by a nucleic acid labeling and detection system (Amersham Pharmacia Bioteck), it was performed according to a conventional method. The results are as shown in Figure 3.o
- pcDNA, pcDNA / Sl, pcDNA / C200, pcDNA / C180, pcDNA / C160, and pcDNAZN40 were each introduced into COS-7 cells using SuperFect Transfection Reagent (manufactured by Qiagen) and allowed to stand on a 60 mm dish for 48 hours. , Collected. The recovered cells were resuspended in SDS lysis buffer (100 ⁇ L). The sample thus obtained was heated for 3 minutes and then centrifuged. The supernatant was electrophoresed on a 14% SDS-PAGE gel. Then, the protein was transferred to a nitrocellulose membrane (Nippon Bio-Rad Laboratories).
- the -trocellulose membrane was incubated with a mouse anti-pertussis toxin polyclonal antiserum, and further supplemented with goat anti-mouse IgG-horseradish peroxidase conjugate (Bio-RadLab.). Blotting detection reagents (manufactured by Amersham Biosciences) [trowel processing was performed and the expression of the antigen protein was analyzed. The result was as shown in FIG. It was confirmed that C180 and C200 were strongly expressed in COS-7 cells.
- mice using pcDNA, pcDNA / Sl, pcDNA / C200, pcDNA / C180, pcDNA / C160, and pcDNAZN40, respectively, using a gene gun (Heilio Gene Gun; manufactured by Bio-Rad Lab .; helium gas pressure 400 psi). (5 weeks old; 5 animals, group Z) were intradermally inoculated three times at 14 day intervals. For each inoculation, 2 g of plasmid DNA and 0.5 mg of gold particles (manufactured by Bio-Rad Lab.) Were used. On days 17, 25, 33, and 41 from the start of the test, blood was collected from the tail vein of each mouse to obtain mouse serum.
- anti-PT-IgG antibody An anti-pertussis toxin IgG antibody (hereinafter referred to as “anti-PT-IgG antibody”) in mouse serum was prepared using an alkaline phosphatase-labeled goat anti-mouse IgG antibody (southern Biotechnology Associates Inc., Birmingham, AL) as a secondary antibody. was measured by ELISA.
- mice inoculated with pcDNA, pcDNA / Sl, pcDNA / C200, pcDNA / C180, pcDNAZC160, and pcDNA / N40 were perfused with pertussis toxin (2 g, manufactured by Seikagaku Corporation) in PBS. (0.5 mL) solution was intraperitoneally administered, and three days later, blood was collected from the tail vein. The peripheral blood leukocyte count (WBC) in this blood was measured using a Coulter counter (manufactured by Beckman Coultor K.K.). The result was as shown in FIG.
- pcDNA control
- pcDNA / C180-9K control
- pcDNA / C180-129G pcDNAZC180-9KZ129G
- pcDNAZC180-9KZ129G was transfected into COS-7 cells using SuperFect Transfection Reagent (manufactured by Qiagen).
- stable expression strains were selected and cloned using 500 gZmL Geneticin (Sigma). The results were as shown in FIG.
- Cell lines expressing C180-9KZ129G showed significantly less cytotoxicity to CHO cells with fewer dead cells than cell lines expressing C180-9K and C180-129G.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006511177A JPWO2005090576A1 (ja) | 2004-03-18 | 2005-03-14 | 百日咳感染症予防用dna構築物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-078963 | 2004-03-18 | ||
JP2004078963 | 2004-03-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005090576A1 true WO2005090576A1 (ja) | 2005-09-29 |
Family
ID=34993708
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/004430 WO2005090576A1 (ja) | 2004-03-18 | 2005-03-14 | 百日咳感染症予防用dna構築物 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JPWO2005090576A1 (ja) |
WO (1) | WO2005090576A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140302558A1 (en) * | 2011-12-21 | 2014-10-09 | Bionet-Asia, Co. Ltd. | Modified bordetella pertussis strains |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1340373C (en) * | 1986-01-28 | 1999-02-02 | Rino Rappuoli | Cloning and sequencing of the dna fragment which codes for the five subunits of the pertussis toxin, a hybrid plasmid containing the dna fragment and micro-organisms transformed by the hybrid plasmid and capable of expressing all or some of the subunits of the pertussis toxin |
-
2005
- 2005-03-14 WO PCT/JP2005/004430 patent/WO2005090576A1/ja active Application Filing
- 2005-03-14 JP JP2006511177A patent/JPWO2005090576A1/ja active Pending
Non-Patent Citations (5)
Title |
---|
BURNETTE W.N. ET AL: "Pertussis Toxin S1 Mutant with Reduced Enzyme Activity and a Conserved Protective Epitope", SCIENCE, vol. 242, October 1988 (1988-10-01), pages 72 - 74, XP000106553 * |
KAMACHI K. ET AL: "DNA vaccine encoding pertussis toxin S1 subunit induces protection against Bordetella pertussis in mice", VACCINE, vol. 21, no. 31, October 2003 (2003-10-01), pages 4609 - 4615, XP004467343 * |
KAMACHI K. ET AL: "Expression of a C Terminally Truncated Form of Pertussis Toxin S1 Subunit Effectively Induces Protection against Pertussis Toxin following DNA-Based Immunization", INFECTION AND IMMUNITY, vol. 72, no. 7, July 2004 (2004-07-01), pages 4293 - 4296, XP002997636 * |
KAMACHI K. ET AL: "Hen'i Hyakunichizeki Dokuso Idenshi o Mochiita Hyakunichizeki DNA Waccine no Kaihatsu Kenkyu", JAPANESE JOURNAL OF BACTERIOLOGY, vol. 58, no. 1, 2003, pages 191, XP002997635 * |
PIZZA M. ET AL: "Mutants of Pertussis Toxin Suitable for Vaccine Development", SCIENCE, vol. 246, October 1989 (1989-10-01), pages 497 - 500, XP001016264 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140302558A1 (en) * | 2011-12-21 | 2014-10-09 | Bionet-Asia, Co. Ltd. | Modified bordetella pertussis strains |
US9187754B2 (en) * | 2011-12-21 | 2015-11-17 | Bionet-Asia, Co. Ltd. | Modified Bordetella pertussis strains |
Also Published As
Publication number | Publication date |
---|---|
JPWO2005090576A1 (ja) | 2008-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111088283B (zh) | mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗 | |
INCHAUSPE et al. | Plasmid DNA expressing a secreted or a nonsecreted form of hepatitis C virus nucleocapsid: comparative studies of antibody and T-helper responses following genetic immunization | |
EP1328653B1 (en) | Highly expressible genes | |
EP3441085A1 (en) | Homodimeric protein constructs | |
MX2012004967A (es) | Proteinas de consenso del virus de la fiebre aftosa (fmdv), secuencias codificantes para estas y vacunas fabricadas a partir de estas. | |
EA012037B1 (ru) | Поливалентные вакцины, содержащие рекомбинантные вирусные векторы | |
EP0941315A1 (en) | Immune responses using compositions containing stress proteins | |
KR20200101416A (ko) | B형 간염 바이러스(hbv) 백신 및 그 용도 | |
CN111533812A (zh) | 针对sars-cov-2病毒的dna疫苗及其用途 | |
WO2023051701A1 (zh) | 抗SARS-CoV-2感染的mRNA、蛋白以及抗SARS-CoV-2感染的疫苗 | |
WO2023036191A1 (zh) | 新型冠状病毒SARS-CoV-2的Delta变异株疫苗与应用 | |
WO2019076218A1 (zh) | H3n2亚型流感病毒血凝素蛋白的突变体及其应用 | |
US10548973B2 (en) | Polypeptide carrier for presenting target polypeptide and uses thereof | |
JPH06509237A (ja) | ワクチンとしてのネコ白血病ウィルスgp70からの融合蛋白質 | |
CN116478296B (zh) | 截短的呼吸道合胞病毒f蛋白及其用途 | |
WO2022085648A1 (ja) | 融合タンパク質及びワクチン | |
WO2005090576A1 (ja) | 百日咳感染症予防用dna構築物 | |
CN113801206B (zh) | 利用受体识别域诱导抗新冠病毒中和抗体的方法 | |
WO2021039873A1 (ja) | ウイルスの非構造タンパク質が担持された複合タンパク質単量体、当該単量体の会合体、及び当該会合体を有効成分とするコンポーネントワクチン | |
CN117003885A (zh) | H5n8禽流感广谱性疫苗的开发及其应用 | |
CA2370278C (en) | Chimeric lyssavirus nucleic acids and polypeptides | |
KR20120047780A (ko) | 호흡기 신시치아 바이러스 백신 조성물 및 그의 제조방법 | |
CN116904489B (zh) | 一种鸭坦布苏病毒核酸疫苗及应用 | |
WO2022242649A1 (zh) | 一种新型冠状病毒SARS-CoV-2突变体疫苗与应用 | |
US7238672B1 (en) | Chimeric lyssavirus nucleic acids and polypeptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006511177 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |